@article{aae82e02a1494c04bc4b5ea33f254f95,
title = "A European paediatric cancer mission: aspiration or reality?",
author = "Kearns, \{Pamela R.\} and Gilles Vassal and Ruth Ladenstein and Martin Schrappe and Andrea Biondi and Patricia Blanc and Angelika Eggert and Anita Kienesberger and Olga Kozhaeva and Rob Pieters and Kjeld Schmiegelow",
note = "Funding Information: PRK reports personal fees from Bristol-Myers Squibb (BMS), Genzyme, Janssen, and AbbVie (outside the submitted work), and is president of the Society of Paediatric Oncology Europe (SIOPE) and a board member of the European Innovative Therapeutics for Children with Cancers (ITCC) network and the ACCELERATE international multistakeholder platform. GV is a board member of SIOPE; president of the ITCC network; chair of the ACCELERATE international multistakeholder platform; and adviser (does not accept personal remuneration) in paediatric oncology drug development for AstraZeneca, Bayer, BMS, Celgene, Incyte, Ipsen, Lilly, Merck, Novartis, Pfizer, Roche/Genentech, Servier, Takeda, and Tesaro. RL is a board member of SIOPE. MS reports grants from Deutsche Krebshilfe, Bonn, Germany; reports personal fees from JazzPharma; reports personal fees, speaker's board, and support for research from Servier (outside the submitted work); and is a board member of SIOPE. AB is an advisory board member of Novartis, Celgene, Incyte, and BMS (outside the submitted work). AE is a member of a working group within the activities of the national (German) decade against cancer. AK reports a memorandum of understanding with SIOPE and PanCare. OK is employed by SIOPE. All other authors declare no competing interests. ",
year = "2019",
month = sep,
doi = "10.1016/S1470-2045(19)30487-5",
language = "English",
volume = "20",
pages = "1200--1202",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Elsevier Ltd.",
number = "9",
}